Xilio Therapeutics Appoints Akintunde Bello, Ph.D., to its Board of Directors
Provided By GlobeNewswire
Last update: Jun 10, 2025
WALTHAM, Mass., June 10, 2025 (GLOBE NEWSWIRE) -- Xilio Therapeutics, Inc. (Nasdaq: XLO), a clinical-stage biotechnology company discovering and developing tumor-activated immuno-oncology therapies for people living with cancer, today announced the appointment of Akintunde (Tunde) Bello, Ph.D., to the company’s board of directors.
Read more at globenewswire.com
